About SAGA Diagnostics
At SAGA Diagnostics, we are at the forefront of revolutionizing the earlier detection of Molecular Residual Disease (MRD) to inform personalized treatment for patients. Our proprietary MRD testing platform aids patients, oncologists, clinical researchers, and drug developers to confidently detect residual disease post-curative intent therapy and monitor response to therapy with unprecedented sensitivity and specificity.
Our accomplished team comprises some of the industry's most seasoned liquid biopsy experts, united in a shared promise to detect and intercept molecular residual disease as early as possible for every patient. SAGA has developed a unique tumor-informed MRD platform that utilizes a hybrid of next-generation sequencing (NGS) and novel digital PCR technology. This innovative approach tracks patient-specific structural variants to detect MRD early and accurately, providing an essential tool for patient care.
FAQs
- When was SAGA Diagnostics founded?
- SAGA Diagnostics was founded in 2016.
- Who is the CEO of SAGA Diagnostics?
- Peter Collins is the CEO.
- What industries or markets does SAGA Diagnostics operate in?
- SAGA Diagnostics operates in the following markets: Molecular Diagnostics, Oncology, Liquid Biopsy, Next Generation Sequencing (NGS), Digital PCR Technology, Personalized Medicine, Clinical Research, Pharmaceutical Development, Healthcare Technology, and Cancer Treatment.
- How many employees does SAGA Diagnostics have?
- SAGA Diagnostics has 11-50 employees.
- Where does SAGA Diagnostics have employees?
- SAGA Diagnostics has employees in Sweden.
- Is SAGA Diagnostics hiring?
- Yes, SAGA Diagnostics has 10 open remote jobs.
- Does SAGA Diagnostics support remote work or working from home?
- Yes, SAGA Diagnostics is a remote-friendly company.
- Does SAGA Diagnostics offer a four-day work week?
- No, SAGA Diagnostics does not offer a four-day work week.
- What is SAGA Diagnostics's website?
- SAGA Diagnostics's website is sagadiagnostics.com.
Sweden
United States only
